In:
Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 10, No. 14 ( 2004-07-15), p. 4709-4716
Abstract:
Purpose: Because the tumor stage is the most significant prognostic factor for non-small cell lung cancer (NSCLC) and given that NSCLC [18F]fluorodeoxyglucose (18F-FDG) uptake appears to have prognostic significance, we examined the relationship between NSCLC 18F-FDG uptake and surgical stage. Experimental Design: One hundred seventy-eight patients with a proven diagnosis of NSCLC were enrolled, then imaged with 18F-FDG positron emission tomography and their disease thoroughly staged. Primary tumor size at computed tomography and 18F-FDG uptake were compared to overall tumor stage and to T, N, and M stage descriptors. Tumor uptake was quantitated by maximum pixel-standardized uptake value (maxSUV) and then partial volume corrected for lesion size using recovery coefficients. Results: A significant difference in tumor size was associated with tumors of different TNM stage, T status, N status, or M status. Similarly, the primary tumor maxSUV was significantly associated with TNM stage, T status, and M status. However, we observed no significant difference in the partial-volume-corrected tumor maxSUV for different stages; different T, N, or M descriptors; tumors without evidence of spread (N0M0) versus tumors with nodal spread (N1,2,3M0); or tumors without spread (N0M0) versus all others. Conclusions: We found an association between tumor stage and 18F-FDG maxSUV, but this relationship disappeared after correction of tumor uptake for lesion size. Therefore, if partial-volume-corrected 18F-FDG uptake is prognostic of NSCLC outcome, it is not on the basis of a relationship with tumor stage but through a different mechanism.
Type of Medium:
Online Resource
ISSN:
1078-0432
,
1557-3265
DOI:
10.1158/1078-0432.CCR-03-0773
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2004
detail.hit.zdb_id:
1225457-5
detail.hit.zdb_id:
2036787-9
Bookmarklink